Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

50
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
50
Hepatic Portal System01:21

Hepatic Portal System

3.7K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
3.7K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

67
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
67
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

319
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
319
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.5K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.5K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

66
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
66

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Accessibility and harmonization of biochemical tests for diagnosis and monitoring of Porphyrias in the United States: Recommendations by members of the American Porphyrias Expert Collaborative (APEX).

Molecular genetics and metabolism·2026
Same author

CBASS limits bacteriophage production while maintaining cell viability in Pseudomonas aeruginosa.

Cell host & microbe·2026
Same author

Regulatory T Cells and Tumor-Associated Macrophages Colocalize in Pediatric Hepatoblastoma.

The Journal of surgical research·2026
Same author

CBASS limits bacteriophage production while maintaining cell viability in <i>Pseudomonas aeruginosa</i>.

bioRxiv : the preprint server for biology·2026
Same author

Sequence Analysis of Two B1 Mycobacteriophages, ElvisPhasley and Mesmerelda.

microPublication biology·2026
Same author

A transcription regulator atlas identifies TOX3 as an Atoh1 coactivator in cerebellar development and tumorigenesis.

Proceedings of the National Academy of Sciences of the United States of America·2026

Related Experiment Video

Updated: Nov 9, 2025

Visualization and Analysis of Blood Flow and Oxygen Consumption in Hepatic Microcirculation: Application to an Acute Hepatitis Model
10:40

Visualization and Analysis of Blood Flow and Oxygen Consumption in Hepatic Microcirculation: Application to an Acute Hepatitis Model

Published on: August 4, 2012

12.9K

The acute hepatic porphyrias.

Bruce Wang1

  • 1Department of Medicine, University of California San Francisco, San Francisco, CA, USA.

Translational Gastroenterology and Hepatology
|April 7, 2021
PubMed
Summary

Acute hepatic porphyrias (AHP) are inherited heme biosynthesis disorders causing severe neurovisceral attacks. Early diagnosis and trigger avoidance are crucial for managing this rare but serious condition.

Area of Science:

  • Biochemistry
  • Genetics
  • Neurology

Background:

  • Acute hepatic porphyrias (AHP) are a group of four inherited disorders affecting heme biosynthesis.
  • Elevated porphyrin precursors, delta-aminolevulinic acid (ALA), cause severe neurovisceral symptoms during acute attacks.
  • Mutation carrier prevalence is higher than previously thought (1 in 1,500), but symptomatic AHP affects only ~1%.

Purpose of the Study:

  • To summarize the understanding of acute hepatic porphyrias, including their pathophysiology, diagnosis, and management.
  • To highlight the challenges in diagnosing AHP due to non-specific symptoms.
  • To emphasize the importance of genetic screening and patient education.

Main Methods:

  • Review of current literature on AHP.
Keywords:
Porphyriagenetic diseasehemeneurovisceral attacksrare diseases

More Related Videos

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.1K
Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

10.6K

Related Experiment Videos

Last Updated: Nov 9, 2025

Visualization and Analysis of Blood Flow and Oxygen Consumption in Hepatic Microcirculation: Application to an Acute Hepatitis Model
10:40

Visualization and Analysis of Blood Flow and Oxygen Consumption in Hepatic Microcirculation: Application to an Acute Hepatitis Model

Published on: August 4, 2012

12.9K
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.1K
Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

10.6K
  • Discussion of diagnostic criteria, including biochemical (ALA, PBG levels) and genetic testing.
  • Outline of treatment strategies, including heme administration and long-term management.

    • Main Results:

    • Symptomatic AHP attacks are characterized by severe abdominal pain, autonomic nerve injury, and central/peripheral nervous system involvement.
    • Diagnosis is often delayed due to non-specific symptoms, necessitating biochemical and genetic confirmation.
    • Heme therapy downregulates ALA production, and long-term management focuses on trigger avoidance and family screening.

    Conclusions:

    • AHP requires prompt diagnosis through biochemical and genetic testing.
    • Effective management involves heme administration and comprehensive patient/family education on trigger avoidance.
    • Increased awareness and screening are vital for improving outcomes in AHP patients.